

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINOPHARM GROUP CO. LTD.*

國藥控股股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

CHANGE OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of Sinopharm Group Co. Ltd. (the “**Company**”) announces that Mr. Ngai Wai Fung ceased to be the joint company secretary of the Company with effect from 24 August 2011.

The Board also announces that Dr. Liu Wei has been appointed as the joint company secretary of the Company for a term from 24 August 2011 to 22 September 2012. The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) has granted a waiver to the Company from strict compliance with the requirements under Rules 8.17 and 19A.16 of the Rules Governing the Listing of Securities of the Hong Kong Stock Exchange (the “**Listing Rules**”) from the appointment date of Dr. Liu to 22 September 2012 on the condition that Mr. Wu Aimin (the other joint company secretary of the Company who does not possess full qualification as required under Rule 8.17 of the Listing Rules) will be assisted by Dr. Liu to acquire the relevant experience within the meaning of Rule 8.17(3) of the Listing Rules and to discharge his duties as the joint company secretary of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. Ngai for his contribution during his tenure as the joint company secretary and its warm welcome to Dr. Liu of his appointment as the joint company secretary of the Company.

BIOGRAPHICAL DETAILS

Dr. Liu Wei

Dr. Liu, aged 54, graduated from the Northwest University of China, the Chinese University of Political Science and Law, the University of Cambridge and the University of Hong Kong, with a bachelor in Chinese literature, a master degree in law, a PhD in Law respectively. He also completed his Common Professional Examination (CPE) with Manchester University in England, as well as a Postgraduate Certificate in Laws (PCLL) with the University of Hong Kong. Dr. Liu has PRC lawyer qualification and is a solicitor qualified to practice law in Hong Kong and in England.

He has extensive exposure in corporate finance and corporate governance of listed companies and is a partner of DLA Piper. Dr. Liu is serving as one of the joint company secretaries of China Southern Airlines Co., Ltd. (a company listed on the Hong Kong Stock Exchange).

By order of the Board
Sinopharm Group Co. Ltd.
She Lulin
Chairman

Shanghai, the PRC

24 August 2011

As at the date of this announcement, the executive director of the Company is Mr. Wei Yulin; the non-executive directors of the Company are Mr. She Lulin, Mr. Wang Qunbin, Mr. Chen Wenhao, Mr. Zhou Bin, Mr. Chen Qiyu, Mr. Deng Jindong, Mr. Fan Banghan and Mr. Liu Hailiang; and the independent non-executive directors of the Company are Mr. Wang Fanghua, Mr. Tao Wuping, Mr. Xie Rong and Mr. Zhou Bajun.

* *The Company is registered as a non-Hong Kong company under Part XI of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong) under its Chinese name and the English name "Sinopharm Group Co. Ltd."*